His­toIn­dex brings new CEO on Board

BioSpectrum (Asia) - - People News -

Sin­ga­pore based His­toIn­dex has ap­pointed Dr Poon Thong Yuen as its new Chief Ex­ec­u­tive Of­fi­cer (CEO). Dr Poon takes over from Dr Gideon Ho, who will con­tinue to drive the global busi­ness growth of the com­pany as the Chief Com­mer­cial Of­fi­cer (CCO).

Dr Poon was most re­cently Chief In­vest­ment Of­fi­cer of Zi­com MedTacc, a Sin­ga­pore-based MedTech in­vestor that has sup­ported var­i­ous start-up com­pa­nies, in­clud­ing His­toIn­dex, from prod­uct pro­to­typ­ing to mar­ket adop­tion. Zi­com MedTacc is a co-in­vestor of His­toIn­dex, to­gether with SEEDS Cap­i­tal (the in­vest­ment arm of En­ter­prise Sin­ga­pore).

Dr Poon is a sea­soned in­vest­ment pro­fes­sional with more than a decade of cor­po­rate ex­pe­ri­ences with health­care ser­vices, ther­a­peu­tic drugs and med­i­cal de­vices, in­clud­ing former board di­rec­tor­ship roles in com­pa­nies such as Ar­ti­san Pharma (ac­quired by Asahi Ka­sei Pharma), In­vi­ra­gen (ac­quired by Takeda Phar­ma­ceu­ti­cal) and Forma Ther­a­peu­tics (large col­lab­o­ra­tion agree­ment with Cel­gene).

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.